查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813850

美國小分子藥物 CDMO 市場規模、佔有率和趨勢分析報告：按藥物類型、產品、應用和細分市場預測，2025-2033 年

U.S. Small Molecule CDMO Market Size, Share & Trends Analysis Report By Drug Type (Generics, Innovators), By Product (APIs, Finished Drug Products), By Application (Oncology, CVD, CNS Conditions), And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國小分子藥物CDMO市場摘要

預計 2024 年美國小分子藥物 CDMO 市值將達到 268.5 億美元，到 2033 年將達到 473.8 億美元，2025 年至 2033 年的複合年成長率為 6.68%。

市場成長的動力源自於整個醫藥價值鏈對外包需求的不斷成長。製藥公司，尤其是中小企業和虛擬生物技術公司，越來越依賴CDMO來縮短上市時間、最佳化研發成本，並獲得製劑、製程開發、法規事務等方面的專業知識。

此外，製藥業的整合和日益成長的成本壓力迫使品牌藥和學名藥公司精簡內部營運，專注於核心競爭力。這為美國CDMO創造了更大的機會，使其不僅能夠支持國內客戶，還能服務於那些追求高品質並符合嚴格FDA法規的客戶。領先的CDMO在產能擴張、持續生產和綠色化學製程方面的投資也持續成長。

美國小分子CDMO市場主要受小分子在FDA核准和在研產品線中持續主導的驅動。到2023年，美國FDA核准的新分子藥物（NME）中超過60%將是小分子，包括Ogsiveo（一種用於治療纖維瘤的藥物）和Zurzuvae（一種用於治療產後憂鬱症的藥物）等藥物。這種穩定的趨勢正在為能夠提供全面服務（包括配方、放大和監管批量生產）的CDMO帶來巨大且持續的需求。占美國早期研發大部分的中小型生技公司通常缺乏內部製造能力，而是依賴CDMO進行臨床前和商業生產。加速高價值治療藥物上市時間的需求，特別是在腫瘤學、罕見疾病和中樞神經系統疾病等領域，進一步加速了向具有從 I 期到 III 期支持能力的靈活的美國CDMO 進行外包。

此外，CDMO 正在進行戰略投資，以擴大美國的生產和開發佈局，以滿足國內創新者和尋求進入美國市場的外國生物製藥公司的需求。例如，Cambrex 在其位於北卡羅來納州海波因特的工廠投資超過 5000 萬美元，以擴展其小分子製程開發和原料藥製造能力。同樣，賽默飛世爾科技也透過收購 Patheon 並隨後升級美國網路來擴展其在美國的生產能力。總部位於美國的 CDMO 還具有顯著的監管和物流優勢，因為在美國境內生產可以降低供應鏈的複雜性，並有助於遵守 FDA 的現行良好生產規範 (cGMP)。

目錄

第1章調查方法與範圍

第2章執行摘要

第 3 章美國小分子藥物 CDMO 市場：變數、趨勢與範圍

  • 市場體系展望
  • 美國小分子CDMO市場動態
  • 技術格局
  • 定價模式分析
  • 美國小分子 CDMO 市場：分析工具

第4章：美國小分子藥物 CDMO 市場：產品預估與趨勢分析

  • 細分儀表板
  • 美國小分子藥物CDMO市場：產品差異分析
  • 美國小分子藥物 CDMO 市場規模與趨勢分析（按產品，2021-2033 年）
  • 活性藥物成分（API）
  • 成品藥品

第5章美國小分子藥物CDMO市場：按藥物類型估計和趨勢分析

  • 細分儀表板
  • 美國小分子藥物CDMO市場：藥物類型變化分析
  • 美國小分子藥物 CDMO 市場規模及趨勢分析（按藥物類型，2021-2033 年）
  • 創新者
  • 學名藥

第6章：美國小分子藥物CDMO市場：應用評估與趨勢分析

  • 細分儀表板
  • 美國小分子藥物CDMO市場：應用趨勢分析
  • 美國小分子藥物 CDMO 市場規模與趨勢分析（按應用，2021-2033 年）
  • 腫瘤學
  • 心血管疾病
  • 中樞神經系統 (CNS) 疾病
  • 自體免疫/炎症
  • 其他

第7章美國小分子藥物 CDMO 市場：按產品、藥物類型和應用進行的區域估計和趨勢分析

  • 區域市場儀表板
  • 全球區域市場概況
  • 2021-2033 年市場規模、預測與趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 公司分類
  • 美國小分子藥物CDMO市佔率分析（2024年）
  • 公司簡介
    • Lonza, Catalent, Inc.
    • Thermo Fisher Scientific Inc.
    • Cambrex Corporation
    • Bellen Chemistry
    • Siegfried Holding AG
    • Recipharm AB
    • Eurofins Scientific
    • Aurigene Pharmaceutical Services Ltd
    • CordenPharma International
Product Code: GVR-4-68040-702-9

U.S. Small Molecule CDMO Market Summary

The U.S. small molecule CDMO market size was estimated at USD 26.85 billion in 2024 and is projected to reach USD 47.38 billion by 2033, growing at a CAGR of 6.68% from 2025 to 2033. The growth of the market is due to the rising demand for outsourcing across the pharmaceutical value chain. Pharmaceutical companies, especially small to mid-sized firms and virtual biotech's, increasingly rely on CDMOs to reduce time-to-market, optimize R&D expenditure, and access specialized capabilities in formulation, process development, and regulatory compliance.

In addition, consolidation in the pharmaceutical industry and growing cost pressures have pushed both innovator and generic drug companies to streamline internal operations and focus on core competencies. This has expanded opportunities for U.S.-based CDMOs to support not only domestic but also clients seeking quality and compliance with stringent FDA regulations. Increasing investments in capacity expansion, continuous manufacturing, and green chemistry processes by leading CDMOs are also contributing to long-term growth.

The U.S. small molecule CDMO market is mainly driven by the ongoing dominance of small molecule drugs in FDA approvals and active pipelines. In 2023, over 60% of the new molecular entities (NMEs) approved by the U.S. FDA were small molecules, including drugs like Ogsiveo (for desmoid tumors) and Zurzuvae (for postpartum depression). This steady trend creates a significant and recurring demand for CDMOs that can provide comprehensive services such as formulation, scale-up, and regulatory batch manufacturing. Small and mid-sized biotech companies, which make up most of the early-stage R&D in the U.S., often lack in-house manufacturing capabilities and instead depend on CDMOs for both preclinical and commercial production. The need to reduce time-to-market for high-value therapeutics-especially in fields like oncology, rare diseases, and CNS disorders-further speeds up outsourcing to flexible, U.S.-based CDMOs with Phase I-III support capabilities.

Moreover, the strategic investment by CDMO companies to expand their U.S. manufacturing and development footprint, catering to both domestic innovators and foreign biopharma looking for U.S. market access. For instance, Cambrex invested over $50 million in its High Point, North Carolina facility to expand process development and API manufacturing capacity for small molecules. Similarly, Thermo Fisher Scientific has been expanding its U.S. capacity through its acquisition of Patheon and subsequent upgrades across its U.S. network. There's also a strong regulatory and logistics advantage for U.S.-based CDMOs, as manufacturing within the U.S. reduces supply chain complexity and supports compliance with FDA current Good Manufacturing Practices (cGMP).

U.S. Small Molecule CDMO Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. small molecule CDMO market report based on product, drug type, application and region.

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Active Pharmaceutical Ingredients (API)
  • Finished Drug Products
  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Innovators
  • Generics
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Cardiovascular Disease
  • Central Nervous System (CNS) Conditions
  • Autoimmune/Inflammation
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Small Molecule CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. U.S. Small Molecule CDMO Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technological Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. U.S. Small Molecule CDMO Market: Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis

Chapter 4. U.S. Small Molecule CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Small Molecule CDMO Market Product Movement Analysis
  • 4.3. U.S. Small Molecule CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Active Pharmaceutical Ingredients (API)
    • 4.4.1. Active Pharmaceutical Ingredients (API) Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5. Finished Drug Products
    • 4.5.1. Finished Drug Products Market Estimates and Forecasts, 2021 - 2033 (USD million)

Chapter 5. U.S. Small Molecule CDMO Market: Drug Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Small Molecule CDMO Market Drug Type Movement Analysis
  • 5.3. U.S. Small Molecule CDMO Market Size & Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 5.4. Innovators
    • 5.4.1. Innovators Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Generics
    • 5.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Small Molecule CDMO Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Small Molecule CDMO Market Application Movement Analysis
  • 6.3. U.S. Small Molecule CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Cardiovascular Disease
    • 6.5.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Central Nervous System (CNS) Conditions
    • 6.6.1. Central Nervous System (CNS) Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Autoimmune/Inflammation
    • 6.7.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Small Molecule CDMO Market: Regional Estimates & Trend Analysis by Product, Drug Type, Application

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts, Trend Analysis, 2021 to 2033
  • 7.4. North America
    • 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. U.S. Small Molecule CDMO Market Share Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Lonza, Catalent, Inc.
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Product benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Thermo Fisher Scientific Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Cambrex Corporation
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Bellen Chemistry
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Siegfried Holding AG
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Recipharm AB
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Eurofins Scientific
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Aurigene Pharmaceutical Services Ltd
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. CordenPharma International
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives

List of tables

  • Table 1 List of abbreviations
  • Table 2 U.S. Small Molecule CDMO market, by product, 2021 - 2033 (USD Million)
  • Table 3 U.S. Small Molecule CDMO market, by drug type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Small Molecule CDMO market, by application, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Small Molecule CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Segment snapshot
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Parent market outlook, 2024 (USD Million)
  • Fig. 17 Ancillary market outlook, 2024 (USD Million)
  • Fig. 18 U S Small Molecule CDMO market dynamics
  • Fig. 19 Porter's five forces analysis
  • Fig. 20 PESTEL analysis
  • Fig. 21 U S Small Molecule CDMO market Product outlook: Segment dashboard
  • Fig. 22 U S Small Molecule CDMO market, by Product segment: Market share, 2025 & 2033
  • Fig. 23 Active Pharmaceutical Ingredients (API) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Finished Drug Products market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 U S Small Molecule CDMO market Drug Type outlook: Segment dashboard
  • Fig. 26 U S Small Molecule CDMO market, by Drug Type segment: Market share, 2024 & 2033
  • Fig. 27 Innovators market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Generics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 U S Small Molecule CDMO market Application outlook: Segment dashboard
  • Fig. 30 U S Small Molecule CDMO market, by Application segment: Market share, 2024 & 2033
  • Fig. 31 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Cardiovascular Disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Central Nervous System (CNS) Conditions market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Autoimmune/Inflammation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Market participant categorization
  • Fig. 37 Heat map analysis